ORIC PHARMACEUTICALS, INC. (ORIC) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
12/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseORIC / S&P -14.52% / 15.20% |
LoseORIC / S&P ORIC unavailable / 15.00% |
LoseORIC / S&P -30.16% / 50.40% |
| 2026-Q11/3 |
WinORIC / S&P 54.89% / -4.33% |
LoseORIC / S&P ORIC unavailable / 11.30% |
LoseORIC / S&P -24.60% / 27.70% |
| 2025-Q40/3 |
LoseORIC / S&P -31.83% / 2.65% |
LoseORIC / S&P ORIC unavailable / 9.00% |
LoseORIC / S&P -18.13% / 13.40% |
| 2025-Q31/3 |
WinORIC / S&P 18.23% / 8.12% |
LoseORIC / S&P ORIC unavailable / 4.61% |
LoseORIC / S&P -4.42% / 13.45% |
| 2025-Q21/3 |
WinORIC / S&P 81.90% / 10.94% |
LoseORIC / S&P ORIC unavailable / 4.83% |
LoseORIC / S&P 7.39% / 10.63% |
| 2025-Q10/3 |
LoseORIC / S&P -30.86% / -4.27% |
LoseORIC / S&P ORIC unavailable / 4.98% |
LoseORIC / S&P 3.31% / 10.57% |
| 2024-Q40/3 |
LoseORIC / S&P -21.27% / 2.41% |
LoseORIC / S&P ORIC unavailable / 5.25% |
LoseORIC / S&P -7.61% / 6.15% |
| 2024-Q31/3 |
WinORIC / S&P 44.98% / 5.89% |
LoseORIC / S&P ORIC unavailable / 5.89% |
LoseORIC / S&P -9.05% / 6.11% |
| 2024-Q20/3 |
LoseORIC / S&P -48.58% / 4.28% |
LoseORIC / S&P ORIC unavailable / 5.38% |
LoseORIC / S&P -19.27% / 5.12% |
| 2024-Q11/3 |
WinORIC / S&P 49.46% / 10.56% |
LoseORIC / S&P ORIC unavailable / 5.71% |
LoseORIC / S&P -17.35% / 5.59% |
| 2023-Q41/3 |
WinORIC / S&P 52.07% / 11.69% |
LoseORIC / S&P ORIC unavailable / 6.81% |
LoseORIC / S&P -12.44% / 7.78% |
| 2023-Q30/3 |
LoseORIC / S&P -22.04% / -3.27% |
LoseORIC / S&P ORIC unavailable / 7.52% |
LoseORIC / S&P -13.85% / -5.03% |
| 2023-Q22/3 |
WinORIC / S&P 36.14% / 8.74% |
LoseORIC / S&P ORIC unavailable / 9.50% |
WinORIC / S&P 1.40% / -8.57% |
| 2023-Q11/3 |
LoseORIC / S&P -3.23% / 7.50% |
LoseORIC / S&P ORIC unavailable / 10.77% |
WinORIC / S&P -0.90% / -15.69% |
| 2022-Q41/3 |
WinORIC / S&P 84.06% / 7.56% |
LoseORIC / S&P ORIC unavailable / 11.88% |
LoseORIC / S&P ORIC unavailable / -17.99% |
| 2022-Q30/3 |
LoseORIC / S&P -28.57% / -4.88% |
LoseORIC / S&P ORIC unavailable / 13.47% |
LoseORIC / S&P ORIC unavailable / -1.41% |
| 2022-Q20/3 |
LoseORIC / S&P -16.10% / -16.10% |
LoseORIC / S&P ORIC unavailable / 13.71% |
LoseORIC / S&P ORIC unavailable / 11.04% |
| 2022-Q10/3 |
LoseORIC / S&P -63.67% / -4.60% |
LoseORIC / S&P ORIC unavailable / 15.97% |
LoseORIC / S&P ORIC unavailable / 42.23% |
| 2021-Q40/3 |
LoseORIC / S&P -29.70% / 11.03% |
LoseORIC / S&P ORIC unavailable / 15.00% |
LoseORIC / S&P ORIC unavailable / 96.40% |
| 2021-Q31/3 |
WinORIC / S&P 18.20% / 0.58% |
LoseORIC / S&P ORIC unavailable / 10.77% |
LoseORIC / S&P ORIC unavailable / 69.42% |
| 2021-Q20/3 |
LoseORIC / S&P -27.80% / 8.55% |
LoseORIC / S&P ORIC unavailable / 6.58% |
LoseORIC / S&P ORIC unavailable / 51.81% |
| 2021-Q10/3 |
LoseORIC / S&P -27.62% / 6.17% |
LoseORIC / S&P ORIC unavailable / -1.06% |
LoseORIC / S&P ORIC unavailable / 7.39% |
| 2020-Q41/3 |
WinORIC / S&P 35.35% / 12.15% |
LoseORIC / S&P ORIC unavailable / -3.72% |
LoseORIC / S&P ORIC unavailable / -33.42% |
| 2020-Q30/3 |
LoseORIC / S&P -25.85% / 8.93% |
LoseORIC / S&P ORIC unavailable / -2.04% |
LoseORIC / S&P ORIC unavailable / -27.10% |
| 2020-Q20/3 |
LoseORIC / S&P ORIC unavailable / 20.54% |
LoseORIC / S&P ORIC unavailable / -0.46% |
LoseORIC / S&P ORIC unavailable / -27.11% |
| 2020-Q10/3 |
LoseORIC / S&P ORIC unavailable / -19.60% |
LoseORIC / S&P ORIC unavailable / 3.47% |
LoseORIC / S&P ORIC unavailable / -14.75% |
| 2019-Q40/3 |
LoseORIC / S&P ORIC unavailable / 9.07% |
LoseORIC / S&P ORIC unavailable / 5.36% |
LoseORIC / S&P ORIC unavailable / 2.99% |
| 2019-Q30/3 |
LoseORIC / S&P ORIC unavailable / 1.70% |
LoseORIC / S&P ORIC unavailable / 5.02% |
LoseORIC / S&P ORIC unavailable / 0.21% |
| 2019-Q20/3 |
LoseORIC / S&P ORIC unavailable / 4.30% |
LoseORIC / S&P ORIC unavailable / 6.64% |
LoseORIC / S&P ORIC unavailable / 8.65% |
| 2019-Q10/3 |
LoseORIC / S&P ORIC unavailable / 13.65% |
LoseORIC / S&P ORIC unavailable / 8.12% |
LoseORIC / S&P ORIC unavailable / 14.29% |
| 2018-Q40/3 |
LoseORIC / S&P ORIC unavailable / -13.52% |
LoseORIC / S&P ORIC unavailable / 9.05% |
LoseORIC / S&P ORIC unavailable / 18.23% |
| 2018-Q30/3 |
LoseORIC / S&P ORIC unavailable / 7.71% |
LoseORIC / S&P ORIC unavailable / 10.21% |
LoseORIC / S&P ORIC unavailable / 19.06% |
| 2018-Q20/3 |
LoseORIC / S&P ORIC unavailable / 3.43% |
LoseORIC / S&P ORIC unavailable / 9.03% |
LoseORIC / S&P ORIC unavailable / 14.46% |
| 2018-Q10/3 |
LoseORIC / S&P ORIC unavailable / -0.76% |
LoseORIC / S&P ORIC unavailable / 7.68% |
LoseORIC / S&P ORIC unavailable / 12.46% |
| 2017-Q40/3 |
LoseORIC / S&P ORIC unavailable / 6.64% |
LoseORIC / S&P ORIC unavailable / 7.03% |
LoseORIC / S&P ORIC unavailable / 13.82% |
| 2017-Q30/3 |
LoseORIC / S&P ORIC unavailable / 4.48% |
LoseORIC / S&P ORIC unavailable / 5.68% |
LoseORIC / S&P ORIC unavailable / 17.57% |
| 2017-Q20/3 |
LoseORIC / S&P ORIC unavailable / 3.09% |
LoseORIC / S&P ORIC unavailable / 4.83% |
LoseORIC / S&P ORIC unavailable / 17.74% |
| 2017-Q10/3 |
LoseORIC / S&P ORIC unavailable / 6.07% |
LoseORIC / S&P ORIC unavailable / 3.67% |
LoseORIC / S&P ORIC unavailable / 13.32% |
| 2016-Q40/3 |
LoseORIC / S&P ORIC unavailable / 3.82% |
LoseORIC / S&P ORIC unavailable / 2.09% |
LoseORIC / S&P ORIC unavailable / 7.05% |
| 2016-Q30/3 |
LoseORIC / S&P ORIC unavailable / 3.85% |
LoseORIC / S&P ORIC unavailable / 0.20% |
LoseORIC / S&P ORIC unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ORIC total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 34.31% | 20.78% |
| Annualized return | 34.31% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ORIC total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -39.87% | 83.14% |
| Annualized return | -9.67% | 12.86% |
10Y · 2020-04-24 to 2026-08-27
| Metric | ORIC total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -46.68% | 319.30% |
| Annualized return | -6.10% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |